Cerebrovascular Events in 21 105 Patients With Atrial Fibrillation Randomized to Edoxaban Versus Warfarin Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48


Giugliano R. P. , Ruff C. T. , Rost N. S. , Silverman S., Wiviott S. D. , Lowe C., ...Daha Fazla

STROKE, cilt.45, sa.8, ss.2372-2378, 2014 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 45 Konu: 8
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1161/strokeaha.114.006025
  • Dergi Adı: STROKE
  • Sayfa Sayıları: ss.2372-2378

Özet

Background and Purpose-The once-daily oral factor Xa inhibitor, edoxaban, is as effective as warfarin in preventing stroke and systemic embolism while decreasing bleeding in a phase III trial of patients with atrial fibrillation at moderate-high stroke risk. Limited data regarding cerebrovascular events with edoxaban were reported previously.